Typhoid Fever - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 46 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Typhoid Fever - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Typhoid Fever - Pipeline Review, H2 2014', provides an overview of the Typhoid Fever's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Typhoid Fever, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Typhoid Fever and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Typhoid Fever
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Typhoid Fever and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Typhoid Fever products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Typhoid Fever pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Typhoid Fever
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Typhoid Fever pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Typhoid Fever Overview 6
Therapeutics Development 7
Pipeline Products for Typhoid Fever - Overview 7
Pipeline Products for Typhoid Fever - Comparative Analysis 8
Typhoid Fever - Therapeutics under Development by Companies 9
Typhoid Fever - Therapeutics under Investigation by Universities/Institutes 10
Typhoid Fever - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Unknown Stage Products 13
Typhoid Fever - Products under Development by Companies 14
Typhoid Fever - Products under Investigation by Universities/Institutes 15
Typhoid Fever - Companies Involved in Therapeutics Development 16
Novartis AG 16
Shantha Biotechnics Limited 17
Chongqing Zhifei Biological Products Co., Ltd. 18
Prokarium Ltd. 19
Typhoid Fever - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Combination Products 21
Assessment by Target 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
Typhella - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Vi-CRM197 Glycoconjugated Vaccine - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
ViCRM-197 PCMV - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Vi-Diptheria Toxoid Conjugate Typhoid Vaccine - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
typhoid + paratyphoid vaccine (bivalent) - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Vi-PspA Vaccine - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
typhoid fever polysaccharide conjugate vaccine - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Typhetec - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Typhoid-Paratyphoid Vaccine - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Vaccine for Typhoid and Paratyphoid Fever - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Typhoid Fever - Recent Pipeline Updates 39
Typhoid Fever - Dormant Projects 41
Typhoid Fever - Product Development Milestones 42
Featured News & Press Releases 42
Mar 11, 2013: Prokarium And University Of Birmingham Receive £0.4m Grant To Develop Next Generation Vaccines 42
Jun 05, 2008: Emergent BioSolutions Initiates U.S. Phase II Trial of Oral Typhoid Vaccine Candidate 42
Jan 08, 2008: Emergent BioSolutions Announces Final Phase II Clinical Study Results for Typhoid Vaccine 43
Nov 21, 2005: Emergent Biosolutions Starts Clinical Study Of Single-Dose Oral Typhoid Vaccine 43
Aug 30, 2005: Emergent Biosolutions' Typhoid Vaccine Achieves Positive Results In Phase II Clinical Study 44
Oct 30, 2002: Bayer Corporation Submits Additional New Drug Application For Once-Daily Cipro XR. 44
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 46
Disclaimer 46

List of Tables
Number of Products under Development for Typhoid Fever, H2 2014 7
Number of Products under Development for Typhoid Fever - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Comparative Analysis by Unknown Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Products under Investigation by Universities/Institutes, H2 2014 15
Typhoid Fever - Pipeline by Novartis AG, H2 2014 16
Typhoid Fever - Pipeline by Shantha Biotechnics Limited, H2 2014 17
Typhoid Fever - Pipeline by Chongqing Zhifei Biological Products Co., Ltd., H2 2014 18
Typhoid Fever - Pipeline by Prokarium Ltd., H2 2014 19
Assessment by Monotherapy Products, H2 2014 20
Assessment by Combination Products, H2 2014 21
Number of Products by Stage and Target, H2 2014 23
Number of Products by Stage and Route of Administration, H2 2014 25
Number of Products by Stage and Molecule Type, H2 2014 27
Typhoid Fever Therapeutics - Recent Pipeline Updates, H2 2014 39
Typhoid Fever - Dormant Projects, H2 2014 41